{"id":"NCT00092417","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)","officialTitle":"Evaluation of the Safety and Tolerability of a Higher Potency Dose of Varicella Zoster Virus Vaccine Live (Oka/Merck)Among Adults 50 Years of Age or Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-10","primaryCompletion":"2004-06","completion":"2004-06","firstPosted":"2004-09-27","resultsPosted":"2010-06-10","lastUpdate":"2015-10-07"},"enrollment":695,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Healthy"],"interventions":[{"type":"BIOLOGICAL","name":"Comparator: Varicella Zoster Virus Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Comparator: Varicella Zoster Virus Vaccine","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"This study compared the safety and tolerability profile of a higher potency investigational vaccine to that of the investigational vaccine at a lower potency dose.","primaryOutcome":{"measure":"Number of Participants With Vaccine-related Serious Clinical Adverse Experiences (SAEs)","timeFrame":"Day 1-42 post vaccination","effectByArm":[{"arm":"Zoster Vaccine Higher Potency","deltaMin":0,"sd":null},{"arm":"Zoster Vaccine Lower Potency","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["17227688"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":459},"commonTop":["Injection Site Erythema","Injection Site Pain","Injection Site Swelling","Injection Site Pruritus","Headache"]}}